Search

Your search keyword '"Myeloma Proteins chemistry"' showing total 57 results

Search Constraints

Start Over You searched for: Descriptor "Myeloma Proteins chemistry" Remove constraint Descriptor: "Myeloma Proteins chemistry"
57 results on '"Myeloma Proteins chemistry"'

Search Results

1. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.

2. Solution structures of human myeloma IgG3 antibody reveal extended Fab and Fc regions relative to the other IgG subclasses.

4. Detection of three blood donors with multiple myeloma by routine viral individual-donor nucleic acid testing screening.

5. Myeloma-Derived Light Chain Paired with a Diagnostic Monoclonal Antibody Hinders Immunoassay Performance.

6. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].

7. New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies.

8. Human myeloma immunoglobulins of the fourth subclass (IgG4 MAM) contain a fraction with different properties of CH2 domains.

10. Azurophilic granules in myeloma cells.

11. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

12. Naturally occurring structural isomers in serum IgA1 o-glycosylation.

13. Searching for antigen epitope specificities in the monoclonal IgG molecules of patients with multiple myeloma. The description of a monoclonal antibody with a dynein-specific antigen epitope character.

14. Identification and characterization of myeloma-associated antigens in Trichinella spiralis.

15. Increased serum bilirubin level without jaundice in patients with monoclonal gammopathy.

16. Pillars article: an analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med. 1970. 132: 211-250.

17. Implications of the near-planar solution structure of human myeloma dimeric IgA1 for mucosal immunity and IgA nephropathy.

18. Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy.

19. Private idiotypes located on light and heavy chains of human myeloma proteins characterized by monoclonal antibodies.

20. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials.

21. The use of the Congo red-related dye DBACR to recognize the heavy chain-derived abnormality of myeloma immunoglobulins.

22. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.

23. When two-dimensional structure led the way.

24. Instability of monoclonal myeloma protein may be identified as susceptibility to penetration and binding by newly synthesized Congo red derivatives.

25. The structural abnormality of myeloma immunoglobulins tested by Congo red binding.

26. Dealing with intractable protein cores: protein sequencing of the Mcg IgG and the Yvo IgM heavy chain variable domains.

27. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy.

28. Three states of the pFh-fragment (Hinge region) from human myeloma IgG3 Kuc with native-like secondary structure.

29. Four structural risk factors identify most fibril-forming kappa light chains.

30. N-glycosylation influences epitope expression and receptor binding structures in human IgE.

31. [Effect of immunoglobulin G1 Pro 290 residue on structural and biological characteristics of its SH2 domain].

32. Investigation of the cooperative structure of Fc fragments from myeloma immunoglobulin G.

33. NMR study of the interaction between the B domain of staphylococcal protein A and the Fc portion of immunoglobulin G.

34. The Fab region of IgG2 human myeloma proteins does not bear the streptococcal protein G-specific determinant.

35. A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding.

36. Ig light chains are secreted predominantly as monomers.

37. Structure and function of IgE myeloma protein VL from an atopic patient.

38. Serologic crossreactions among primate immunoglobulins.

39. Activation of human complement by totally human monoclonal antibodies.

40. Homogenous IgA monomers, dimers, trimers and tetramers from the same IgA myeloma serum.

41. Characterization of IgA1, IgA2 and secretory IgA carbohydrate chains using plant lectins.

42. Peptic fragments of rat monomeric IgA.

43. IgE heterogeneity and biological activity.

44. Carbohydrate heterogeneity of human myeloma proteins of the IgA1 and IgA2 subclasses.

45. Expression of F4, 8.12, 3I, and 16/6 anti-DNA idiotype-related antigens on cationic human IgG myeloma proteins.

46. Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin.

47. Lectin receptors on IgA isotypes.

48. Antigen recognition and targeted delivery by the single-chain Fv.

49. Antibody variable region glycosylation: biochemical and clinical effects.

50. Crystal structure of human immunoglobulin fragment Fab New refined at 2.0 A resolution.

Catalog

Books, media, physical & digital resources